The latest interim data from XPAND, AirXpanders Inc.’s U.S.-based, head-to-head pivotal study of its new, needle-free, patient-controlled tissue expansion system for mastectomy patients undergoing breast reconstruction, continue to show superior

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In